ArticlePharmaceutics2024

Surface-Available HER2 Levels Alone Are Not Indicative of Cell Response to HER2-Targeted Antibody-Drug Conjugate Therapies.

Molly Major et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.